Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction

• Sponsor: Nanjing Medical University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT06038994
• Collaborator: (none)
• Enrollment: 200
• Location: 1
• Anticipated Duration (Months): 19.9
• Patients Per Site Per Month: 10

Study Details

Study Description

Brief Summary

To evaluate the prognostic value of surem TRAF3IP2 levels in patients with acute myocardial infarction

Condition or Disease	Intervention/Treatment	Phase
Myocardial Infarction, Acute	Other: No intervention

Detailed Description

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients diagnosed with acute myocardial infarction who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the major adverse cardiac events will be evaluated.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 200 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
• Actual Study Start Date: Sep 1, 2023
• Anticipated Primary Completion Date: Apr 30, 2024
• Anticipated Study Completion Date: Apr 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Patients with acute myocardial infarction who experienced CAG Patients with acute myocardial infarction who experienced coronary angiography	Other: No intervention; This is an obvertional study, and there is no intervention.

Outcome Measures

Primary Outcome Measures

1. MACEs (major adverse cardiac events) [1 year]

   MACEs were defined as a composite of cardiac death, hospitalization for myocardial infarction or heart failure

Secondary Outcome Measures

1. cardiac death [1 year]

   and death due to cardiac reasons, such as myocardial infarction or heart failure

2. hospitalization for myocardial infarction or heart failure [1 year]

   hospitalization for myocardial infarction or heart failure

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 90 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients with acute myocardial infarction

2. patients received coronary angiography

3. invasive management within 72 h of hospital admission

Exclusion Criteria:

1. NYHA III-IV

2. malignant tumor

3. acute infection

4. thyroid dysfunction

5. Life expectancy of b1 y

6. Unsuitable for PCI

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Huai'an First People's Hospital	Huai'an	Jiangsu	China	223300

Sponsors and Collaborators

• Nanjing Medical University

Investigators

• Principal Investigator: Shuren Ma, MD., NJMU

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jin Geng, associate doctor, Nanjing Medical University
• ClinicalTrials.gov Identifier: NCT06038994
• Other Study ID Numbers: 20230901
• First Posted: Sep 15, 2023
• Last Update Posted: Sep 15, 2023
• Last Verified: Sep 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Jin Geng, associate doctor, Nanjing Medical University: TRAF3IP2, Myocardial Infarction, Coronary angiography, MACEs
• Additional relevant MeSH terms: Myocardial Infarction; Infarction

Study Results

No Results Posted as of Sep 15, 2023